Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 7, 2015

MEDNAX, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Florida

001-12111

26-3667538

(State or Other Jurisdiction of

Incorporation)

(Commission File

Number)

(IRS Employer Identification No.)

1301 Concord Terrace

Sunrise, Florida 33323

 

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code (954) 384-0175

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 7, 2015, MEDNAX, Inc., a Florida corporation (the “Company”), held its 2015 Annual Shareholders’ Meeting (the “Annual Meeting”). Of the 96,003,021 shares of common stock outstanding and entitled to vote, 83,518,676 shares were represented, constituting a quorum. The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

Proposal 1: All of the Board’s nominees for Director were elected to serve until the Company’s 2016 Annual Shareholders’ Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below:

 

Name

   For      Withheld      Broker
Non-Vote
 

Cesar L. Alvarez

     61,166,462         18,346,893         4,005,321   

Karey D. Barker

     79,207,224         306,131         4,005,321   

Waldemar A. Carlo, M.D.

     75,501,241         4,012,114         4,005,321   

Michael B. Fernandez

     75,197,368         4,315,987         4,005,321   

Paul G. Gabos

     77,526,679         1,986,676         4,005,321   

Pascal J. Goldschmidt, M.D.

     78,804,611         708,744         4,005,321   

Manuel Kadre

     78,975,679         537,676         4,005,321   

Roger J. Medel, M.D.

     77,803,250         1,710,105         4,005,321   

Donna E. Shalala, Ph.D.

     79,455,071         58,284         4,005,321   

Enrique J. Sosa, Ph.D.

     77,323,127         2,190,228         4,005,321   


Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered certified public accounting firm for the 2015 fiscal year was ratified by the shareholders, by the votes set forth in the table below:

 

For

 

Against

 

Abstained

 

Broker

Non-Vote

80,973,713

  2,520,597   24,366   0

Proposal 3: The shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, by the votes set forth in the table below:

 

For

 

Against

 

Abstained

 

Broker

Non-Vote

72,989,522

  6,492,301   31,532   4,005,321


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

MEDNAX, INC.
Date: May 8, 2015 By: /s/ Vivian Lopez-Blanco
Vivian Lopez-Blanco
Chief Financial Officer